Worldwide, cervical cancer is the second most common cancer in women, with over 400,000 cases per year. Identifying High-grade disease early, the immediate pre-cursor to cancer, is a critical component to a good prognosis.   

mtm’s patent protected CINtec® products are adjunctive tools for histology and cytology applications and are based on detecting the over-expression of the cellular protein p16INK4a (p16), a biomarker correlated with the oncogenic transformation of cervical cells’ response to persistent infection with High-risk Human Papillomavirus (HR-HPV). CINtec® Histology is listed in the United States as a Class 1 IVD.